Moody Aldrich Partners’s Soleno Therapeutics SLNO Stock Holding History

Moody Aldrich Partners’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-48,261	Closed	-$1.62M	–	214
2026 Q1	$1.62M	Buy	48,261 +1,955	+4%	+$76.6K	0.29%	115
2025 Q4	$2.14M	Sell	46,306 -4,968	-10%	-$272K	0.4%	108
2025 Q3	$3.47M	Buy	51,274 +9,757	+24%	+$723K	0.66%	79
2025 Q2	$3.48M	Buy	41,517 +11,707	+39%	+$876K	0.67%	66
2025 Q1	$2.13M	Buy	29,810 +196	+0.7%	+$9.54K	0.45%	83
2024 Q4	$1.33M	Buy	+29,614	New	+$1.53M	0.25%	107

Moody Aldrich Partners's SLNO Position: Q2 2026 in Review

Moody Aldrich Partners sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 48,261 shares — an estimated $1.62M sold.

Moody Aldrich Partners first reported a position in SLNO in Q4 2024 and held it in 6 quarters. The position peaked at $3.48M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Moody Aldrich Partners reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Moody Aldrich Partners sold 48,261 Soleno Therapeutics shares in Q2 2026, an estimated $1.62M.
Moody Aldrich Partners first reported a position in Soleno Therapeutics in Q4 2024 and held it in 6 quarters.
Moody Aldrich Partners's Soleno Therapeutics position peaked at $3.48M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.